Our top pick for
Harrow Health Inc is a drug manufacturers-specialty & generic business based in the US. Harrow Health shares (HROW) are listed on the NASDAQ and all prices are listed in US Dollars. Harrow Health employs 125 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$9.89|
|52-week range||$4.65 - $11.24|
|50-day moving average||$9.72|
|200-day moving average||$8.82|
|Wall St. target price||$15.31|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.27|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||2.49%|
|1 month (2021-09-17)||4.21%|
|3 months (2021-07-16)||41.49%|
|6 months (2021-04-16)||23.63%|
|1 year (2020-10-16)||69.35%|
|2 years (2019-10-17)||88.38%|
|3 years (2018-10-17)||195.22%|
|5 years (2016-10-17)||204.31%|
Valuing Harrow Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harrow Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Harrow Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Harrow Health shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Harrow Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.3 million.
The EBITDA is a measure of a Harrow Health's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$62.6 million|
|Operating margin TTM||18.07%|
|Gross profit TTM||$34.4 million|
|Return on assets TTM||9.04%|
|Return on equity TTM||39.24%|
|Market capitalisation||$266 million|
TTM: trailing 12 months
There are currently 980,205 Harrow Health shares held short by investors – that's known as Harrow Health's "short interest". This figure is 1.6% down from 995,919 last month.
There are a few different ways that this level of interest in shorting Harrow Health shares can be evaluated.
Harrow Health's "short interest ratio" (SIR) is the quantity of Harrow Health shares currently shorted divided by the average quantity of Harrow Health shares traded daily (recently around 125990.35989717). Harrow Health's SIR currently stands at 7.78. In other words for every 100,000 Harrow Health shares traded daily on the market, roughly 7780 shares are currently held short.
However Harrow Health's short interest can also be evaluated against the total number of Harrow Health shares, or, against the total number of tradable Harrow Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Harrow Health's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Harrow Health shares in existence, roughly 40 shares are currently held short) or 0.0502% of the tradable shares (for every 100,000 tradable Harrow Health shares, roughly 50 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Harrow Health.
Find out more about how you can short Harrow Health stock.
We're not expecting Harrow Health to pay a dividend over the next 12 months.
Harrow Health's shares were split on a 1:5 basis on 7 February 2013. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Harrow Health shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Harrow Health shares which in turn could have impacted Harrow Health's share price.
Over the last 12 months, Harrow Health's shares have ranged in value from as little as $4.65 up to $11.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harrow Health's is 0.9757. This would suggest that Harrow Health's shares are less volatile than average (for this exchange).
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc. , a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc. , a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.